Physician

Matthew Jacob Kotlove, MD

According to 2025 Medicare claims, Matthew Kotlove, MD (NPI: 1821416645) practices hematology/oncology in the Cincinnati, OH-KY-IN market, with the plurality of this provider's patient population coming from Dearborn, IN. This provider's primary affiliated billing organization is ST ELIZABETH MEDICAL CENTER, INC (NPI: 1932187937; TIN: 610445850) and primary practice location at 47025-8299. Kotlove is affiliated with the Healthcare Solutions Network (ACO ID: A3283), participating under the MSSP model.

Kotlove's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 354 traditional Medicare patients, billed 1,343 HCPCS/CPT codes, and received $66,847 in Medicare payments. The top billing code was 99222 (Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes). Part D data shows 1,618 prescription claims across 228 beneficiaries totaling $3,556,051 in drug costs, led by Revlimid (Lenalidomide). 2021 DME data shows 25 claims. Open Payments data shows 4 records totaling $1,655. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $8,807 to $3,556,051. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	121	200	$13,652
2021	288	779	$56,239
2022	341	858	$61,387
2023	352	818	$59,364
2024	354	1,343	$66,847

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	50	149	$8,807
2016	81	472	$20,543
2017	42	162	$16,566
2018	15	37	$1,916
2019	24	44	$2,830
2020	43	130	$148,758
2021	147	781	$1,588,832
2022	184	1,044	$2,085,669
2023	221	1,380	$2,833,459
2024	228	1,618	$3,556,051

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	25	$2,322
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	55	55	$98
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	44	44	$86
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	270	651	$67
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	29	37	$61
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	193	489	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	43	1,135	$810,941
Lenalidomide	Lenalidomide	39	1,092	$582,377
Calquence	Acalabrutinib Maleate	35	1,050	$500,975
Promacta	Eltrombopag Olamine	26	780	$443,330
Imbruvica	Ibrutinib	13	364	$212,604

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	4	$1,655	Astellas Pharma Global Development
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Matthew Jacob Kotlove, MD?

Tedicare shows public-source Medicare data for Matthew Jacob Kotlove, MD (NPI 1821416645), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Matthew Jacob Kotlove, MD have ACO affiliation data?

Matthew Jacob Kotlove, MD is shown with ACO affiliation data for Healthcare Solutions Network (MSSP, ACO ID A3283).

What billing organization is linked to Matthew Jacob Kotlove, MD?

Matthew Jacob Kotlove, MD is linked to ST ELIZABETH MEDICAL CENTER, INC (billing NPI 1932187937) in the available physician profile data.

Does Matthew Jacob Kotlove, MD have Open Payments data?

Matthew Jacob Kotlove, MD has 4 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.